학술논문
Five-Year Survival Results from the Remodl-B Trial (ISRCTN 51837425) Show Improved Outcomes in Diffuse Large B-Cell Lymphoma Molecular Subgroups from the Addition of Bortezomib to R-CHOP Chemoimmunotherapy
Document Type
Abstract
Author
Davies, Andrew J ; Stanton, Louise ; Caddy, Josh ; Barrans, Sharon ; Wilding, Sam ; Saunders, Geoff N ; Mamot, Christoph ; Novak, Urban ; McMillan, Andrew K.; Fields, Paul A; Collins, Graham P.; Stephens, Richard ; Cucco, Francesco ; Sha, Chulin ; Van Hoppe, Moniek ; Tooze, Reuben M ; Care, Matthew A ; Griffiths, Gareth ; Schuh, Anna; Du, Ming-Qing; Westhead, David R ; Burton, Cathy ; Johnson, Peter
Source
In Blood 15 November 2022 140 Supplement 1:1770-1772
Subject
Language
ISSN
0006-4971